Marcain-Adrenalin (Bupivacaine Hydrochloride, Epinephrine)

Bupivacaine hydrochloride blocks voltage‑gated sodium channels on nerve membranes, stopping the initiation and conduction of nerve impulses. This results in loss of sensation in the targeted area, allowing procedures to be performed without pain.

The dose of Marcain-Adrenalin is determined by the prescribing clinician based on the type of procedure, patient weight, and clinical context. Healthcare professionals calculate the appropriate volume and concentration to achieve effective anesthesia while staying within safety limits.

Safety data in pregnancy and lactation are limited. Use is only recommended when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and it should be administered under specialist guidance.

To order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Marcain-Adrenalin combines bupivacaine with epinephrine, which causes local vasoconstriction. This prolongs the anesthetic effect and reduces systemic absorption compared with plain bupivacaine, allowing longer duration of action and potentially lower total dose.

Store the product at room temperature, preferably below 25 °C, in its original packaging. Protect it from light and moisture, and avoid freezing. Inspect the container for any particulate matter before use.

Marcain-Adrenalin is administered by a qualified healthcare professional via epidural or infiltration injection. The solution is injected directly into the target tissue or epidural space using aseptic technique.

Serious risks include cardiac arrhythmia, seizures, severe allergic reactions (anaphylaxis), methemoglobinemia, and local anesthetic systemic toxicity (LAST). Immediate medical attention is required if any of these occur.

Patients with known hypersensitivity to bupivacaine, epinephrine, or other amide‑type local anesthetics should avoid it. It is also contraindicated in individuals with severe conduction disorders, uncontrolled hypertension, or certain cardiac conditions without careful risk assessment.